[Clinical experiences with mefloquine in tropical malaria--a prospective study].
The therapeutic effects and side effects of mefloquine in falciparum malaria were investigated in an open prospective trial involving 20 patients. None of them had a history of neurologic or psychiatric disorders. Mefloquine was given in a total dose of 1500 mg base. The cure rate was 100%, fever and parasitemia subsided within 3 days. Side effects were vomitus and nausea in 25% of the patients. No neurological or psychiatric disorders were observed. Mefloquine was shown to be a safe therapeutic agent in the dosage used. However, regular follow-up examinations should be done in short intervals because of the possibility of late neuropsychiatric side effects; the patients and their relatives should be informed about this fact.
Universitätsklinikum Rudolf Virchow, Abteilung für Innere Medizin mit Schwerpunkt Infektionskrankheiten, Berlin.
T
T
Held
M
M
Trautmann
T
T
Weinke
S
S
Mravak
D000293:Adolescent; D000328:Adult; D000354:Africa, Western; D000818:Animals; D005260:Female; D005858:Germany; D006801:Humans; D008270:Madagascar; D008288:Malaria / Q000188:drug therapy*; D008297:Male; D015767:Mefloquine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001523:Mental Disorders / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D009422:Nervous System Diseases / Q000139:chemically induced; D010963:Plasmodium falciparum / Q000187:drug effects*; D011446:Prospective Studies; D014195:Travel; D014454:Uganda; D014839:Vomiting / Q000139:chemically induced
D015767:Mefloquine
Klinische Erfahrungen mit Mefloquin bei Malaria tropica--eine prospektive Studie.